Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Renal dopaminergic system: Pathophysiological implications and clinical perspectives.

World journal of nephrology

Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL, Kravetz MC, Rosón MI, Rodríguez Fermepin M, Fernández BE.
PMID: 25949933
World J Nephrol. 2015 May 06;4(2):196-212. doi: 10.5527/wjn.v4.i2.196.

Fluid homeostasis, blood pressure and redox balance in the kidney are regulated by an intricate interaction between local and systemic anti-natriuretic and natriuretic systems. Intrarenal dopamine plays a central role on this interactive network. By activating specific receptors, dopamine...

Cite
Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL, et al. Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World J Nephrol. 2015;4(2):196-212doi: 10.5527/wjn.v4.i2.196.
Choi, M. R., Kouyoumdzian, N. M., Rukavina Mikusic, N. L., Kravetz, M. C., Rosón, M. I., Rodríguez Fermepin, M., & Fernández, B. E. (2015). Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World journal of nephrology, 4(2), 196-212. https://doi.org/10.5527/wjn.v4.i2.196
Choi, Marcelo Roberto, et al. "Renal dopaminergic system: Pathophysiological implications and clinical perspectives." World journal of nephrology vol. 4,2 (2015): 196-212. doi: https://doi.org/10.5527/wjn.v4.i2.196
Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL, Kravetz MC, Rosón MI, Rodríguez Fermepin M, Fernández BE. Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World J Nephrol. 2015 May 06;4(2):196-212. doi: 10.5527/wjn.v4.i2.196. PMID: 25949933; PMCID: PMC4419129.
Copy Download .nbib Format: NLM
Effect of NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, on neurotransmitter receptor systems in aged rats.

European journal of neurology

Araki T, Itoyama Y, Kato H, Oshima Y, Shuto K.
PMID: 10210896
Eur J Neurol. 1998 Nov;5(6):601-608. doi: 10.1046/j.1468-1331.1998.560601.x.

In order to examine the effect of age and nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), we studied the changes on major neurotransmitter receptor systems in 6 (adult) and 24-month-old (aged) Fischer male rats using receptor autoradiography. L-NAME...

Cite
Araki T, Itoyama Y, Kato H, et al. Effect of NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, on neurotransmitter receptor systems in aged rats. Eur J Neurol. 1998;5(6):601-608doi: 10.1046/j.1468-1331.1998.560601.x.
Araki, T., Itoyama, Y., Kato, H., Oshima, Y., & Shuto, K. (1998). Effect of NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, on neurotransmitter receptor systems in aged rats. European journal of neurology, 5(6), 601-608. https://doi.org/10.1046/j.1468-1331.1998.560601.x
Araki, et al. "Effect of NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, on neurotransmitter receptor systems in aged rats." European journal of neurology vol. 5,6 (1998): 601-608. doi: https://doi.org/10.1046/j.1468-1331.1998.560601.x
Araki T, Itoyama Y, Kato H, Oshima Y, Shuto K. Effect of NG-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, on neurotransmitter receptor systems in aged rats. Eur J Neurol. 1998 Nov;5(6):601-608. doi: 10.1046/j.1468-1331.1998.560601.x. PMID: 10210896.
Copy Download .nbib Format: NLM
Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.

American journal of cancer research

Staley A, Tucker K, Yin Y, Zhang X, Fan Y, Zhang Y, Fang Z, Sun W, Suo H, Zhao X, Zhao Z, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL.
PMID: 34873466
Am J Cancer Res. 2021 Nov 15;11(11):5374-5387. eCollection 2021.

Endometrial cancer (EC) is a highly obesity-driven cancer, with limited treatment options. ONC201 is an imipridone that selectively antagonizes the G protein-coupled receptors dopamine receptor D2 and D3 (DRD2/3) and activates human mitochondrial caseinolytic protease P (ClpP). It is...

Cite
Staley A, Tucker K, Yin Y, et al. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. Am J Cancer Res. 2021;11(11):5374-5387
Staley, A., Tucker, K., Yin, Y., Zhang, X., Fan, Y., Zhang, Y., Fang, Z., Sun, W., Suo, H., Zhao, X., Zhao, Z., Prabhu, V. V., Allen, J. E., Zhou, C., & Bae-Jump, V. L. (2021). Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. American journal of cancer research, 11(11), 5374-5387.
Staley, Allison, et al. "Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer." American journal of cancer research vol. 11,11 (2021): 5374-5387.
Staley A, Tucker K, Yin Y, Zhang X, Fan Y, Zhang Y, Fang Z, Sun W, Suo H, Zhao X, Zhao Z, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. Am J Cancer Res. 2021 Nov 15;11(11):5374-5387. eCollection 2021. PMID: 34873466; PMCID: PMC8640798.
Copy Download .nbib Format: NLM
Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.

American journal of cancer research

Staley A, Tucker K, Yin Y, Zhang X, Fan Y, Zhang Y, Fang Z, Sun W, Suo H, Zhao X, Zhao Z, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL.
PMID: 34873466
Am J Cancer Res. 2021 Nov 15;11(11):5374-5387. eCollection 2021.

Endometrial cancer (EC) is a highly obesity-driven cancer, with limited treatment options. ONC201 is an imipridone that selectively antagonizes the G protein-coupled receptors dopamine receptor D2 and D3 (DRD2/3) and activates human mitochondrial caseinolytic protease P (ClpP). It is...

Cite
Staley A, Tucker K, Yin Y, et al. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. Am J Cancer Res. 2021;11(11):5374-5387
Staley, A., Tucker, K., Yin, Y., Zhang, X., Fan, Y., Zhang, Y., Fang, Z., Sun, W., Suo, H., Zhao, X., Zhao, Z., Prabhu, V. V., Allen, J. E., Zhou, C., & Bae-Jump, V. L. (2021). Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. American journal of cancer research, 11(11), 5374-5387.
Staley, Allison, et al. "Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer." American journal of cancer research vol. 11,11 (2021): 5374-5387.
Staley A, Tucker K, Yin Y, Zhang X, Fan Y, Zhang Y, Fang Z, Sun W, Suo H, Zhao X, Zhao Z, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. Am J Cancer Res. 2021 Nov 15;11(11):5374-5387. eCollection 2021. PMID: 34873466; PMCID: PMC8640798.
Copy Download .nbib Format: NLM
Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.

Supportive cancer therapy

Reddy GK, Gralla RJ, Hesketh PJ.
PMID: 18632487
Support Cancer Ther. 2006 Apr 01;3(3):140-2. doi: 10.3816/SCT.2006.n.011.

Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy- induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid- 1, and 5-hydroxytryptamine-3) that were the known targets for...

Cite
Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006;3(3):140-2doi: 10.3816/SCT.2006.n.011.
Reddy, G. K., Gralla, R. J., & Hesketh, P. J. (2006). Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Supportive cancer therapy, 3(3), 140-2. https://doi.org/10.3816/SCT.2006.n.011
Reddy, G Kesava, et al. "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis." Supportive cancer therapy vol. 3,3 (2006): 140-2. doi: https://doi.org/10.3816/SCT.2006.n.011
Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 01;3(3):140-2. doi: 10.3816/SCT.2006.n.011. PMID: 18632487.
Copy Download .nbib Format: NLM
The role of dentate gyrus dopaminergic receptors in the lateral hypothalamic-induced antinociception during persistent inflammatory pain in male rats.

Behavioural brain research

Torkamand F, Aghakhani-Lobnani AM, Khaleghzadeh-Ahangar H, Rashvand M, Rahban M, Haghparast A.
PMID: 34175356
Behav Brain Res. 2021 Aug 27;412:113434. doi: 10.1016/j.bbr.2021.113434. Epub 2021 Jun 24.

The lateral hypothalamus (LH) is one of the key brain areas involved in pain modulation. Also, the dentate gyrus (DG) of the hippocampus expresses various receptors, including dopaminergic receptors. Dopaminergic receptors play a key role in pain transmission and...

Cite
Torkamand F, Aghakhani-Lobnani AM, Khaleghzadeh-Ahangar H, et al. The role of dentate gyrus dopaminergic receptors in the lateral hypothalamic-induced antinociception during persistent inflammatory pain in male rats. Behav Brain Res. 2021;412:113434doi: 10.1016/j.bbr.2021.113434.
Torkamand, F., Aghakhani-Lobnani, A. M., Khaleghzadeh-Ahangar, H., Rashvand, M., Rahban, M., & Haghparast, A. (2021). The role of dentate gyrus dopaminergic receptors in the lateral hypothalamic-induced antinociception during persistent inflammatory pain in male rats. Behavioural brain research, 412113434. https://doi.org/10.1016/j.bbr.2021.113434
Torkamand, Farbod, et al. "The role of dentate gyrus dopaminergic receptors in the lateral hypothalamic-induced antinociception during persistent inflammatory pain in male rats." Behavioural brain research vol. 412 (2021): 113434. doi: https://doi.org/10.1016/j.bbr.2021.113434
Torkamand F, Aghakhani-Lobnani AM, Khaleghzadeh-Ahangar H, Rashvand M, Rahban M, Haghparast A. The role of dentate gyrus dopaminergic receptors in the lateral hypothalamic-induced antinociception during persistent inflammatory pain in male rats. Behav Brain Res. 2021 Aug 27;412:113434. doi: 10.1016/j.bbr.2021.113434. Epub 2021 Jun 24. PMID: 34175356.
Copy Download .nbib Format: NLM
Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa.

European review for medical and pharmacological sciences

Zareifopoulos N, Skaltsa M, Dimitriou A, Karveli M, Efthimiou P, Lagadinou M, Tsigkou A, Velissaris D.
PMID: 34286493
Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4514-4519. doi: 10.26355/eurrev_202107_26243.

OBJECTIVE: Drugs affecting dopaminergic neurotransmission may exert toxic and beneficial effects that persist after discontinuation by modulating gene expression in key brain regions. Drug addiction, cravings and the tardive symptoms associated with chronic exposure to antipsychotics are among the...

Cite
Zareifopoulos N, Skaltsa M, Dimitriou A, et al. Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. Eur Rev Med Pharmacol Sci. 2021;25(13):4514-4519doi: 10.26355/eurrev_202107_26243.
Zareifopoulos, N., Skaltsa, M., Dimitriou, A., Karveli, M., Efthimiou, P., Lagadinou, M., Tsigkou, A., & Velissaris, D. (2021). Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. European review for medical and pharmacological sciences, 25(13), 4514-4519. https://doi.org/10.26355/eurrev_202107_26243
Zareifopoulos, N, et al. "Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa." European review for medical and pharmacological sciences vol. 25,13 (2021): 4514-4519. doi: https://doi.org/10.26355/eurrev_202107_26243
Zareifopoulos N, Skaltsa M, Dimitriou A, Karveli M, Efthimiou P, Lagadinou M, Tsigkou A, Velissaris D. Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4514-4519. doi: 10.26355/eurrev_202107_26243. PMID: 34286493.
Copy Download .nbib Format: NLM
Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis.

Journal of molecular psychiatry

Melka MG, Castellani CA, Laufer BI, Rajakumar RN, O'Reilly R, Singh SM.
PMID: 25408910
J Mol Psychiatry. 2013 Nov 04;1(1):19. doi: 10.1186/2049-9256-1-19. eCollection 2013.

BACKGROUND: The dopamine (DA) hypothesis of schizophrenia proposes the mental illness is caused by excessive transmission of dopamine in selected brain regions. Multiple lines of evidence, including blockage of dopamine receptors by antipsychotic drugs that are used to treat...

Cite
Melka MG, Castellani CA, Laufer BI, et al. Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis. J Mol Psychiatry. 2013;1(1):19doi: 10.1186/2049-9256-1-19.
Melka, M. G., Castellani, C. A., Laufer, B. I., Rajakumar, R. N., O'Reilly, R., & Singh, S. M. (2013). Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis. Journal of molecular psychiatry, 1(1), 19. https://doi.org/10.1186/2049-9256-1-19
Melka, Melkaye G, et al. "Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis." Journal of molecular psychiatry vol. 1,1 (2013): 19. doi: https://doi.org/10.1186/2049-9256-1-19
Melka MG, Castellani CA, Laufer BI, Rajakumar RN, O'Reilly R, Singh SM. Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis. J Mol Psychiatry. 2013 Nov 04;1(1):19. doi: 10.1186/2049-9256-1-19. eCollection 2013. PMID: 25408910; PMCID: PMC4223857.
Copy Download .nbib Format: NLM
Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis: A Literature Review.

Cureus

Kambampati S, Wasim S, Kukkar V, Awad VM, Malik BH.
PMID: 32983669
Cureus. 2020 Aug 23;12(8):e9965. doi: 10.7759/cureus.9965.

Restless Leg Syndrome (RLS), or Willis-Ekbom disease (WED), is an irresistible urge to move the legs, predominantly while resting, sitting, or sleeping, which disrupts sleep and impairs quality of life. RLS can occur secondary to uremia in chronic kidney...

Cite
Kambampati S, Wasim S, Kukkar V, et al. Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis: A Literature Review. Cureus. 2020;12(8):e9965doi: 10.7759/cureus.9965.
Kambampati, S., Wasim, S., Kukkar, V., Awad, V. M., & Malik, B. H. (2020). Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis: A Literature Review. Cureus, 12(8), e9965. https://doi.org/10.7759/cureus.9965
Kambampati, Srikala, et al. "Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis: A Literature Review." Cureus vol. 12,8 (2020): e9965. doi: https://doi.org/10.7759/cureus.9965
Kambampati S, Wasim S, Kukkar V, Awad VM, Malik BH. Restless Leg Syndrome in the Setting of Patients With End-Stage Renal Disease on Hemodialysis: A Literature Review. Cureus. 2020 Aug 23;12(8):e9965. doi: 10.7759/cureus.9965. PMID: 32983669; PMCID: PMC7510539.
Copy Download .nbib Format: NLM
Dopamine in Health and Disease: Much More Than a Neurotransmitter.

Biomedicines

Franco R, Reyes-Resina I, Navarro G.
PMID: 33499192
Biomedicines. 2021 Jan 22;9(2). doi: 10.3390/biomedicines9020109.

Dopamine is derived from an amino acid, phenylalanine, which must be obtained through the diet. Dopamine, known primarily to be a neurotransmitter involved in almost any higher executive action, acts through five types of G-protein-coupled receptors. Dopamine has been...

Cite
Franco R, Reyes-Resina I, Navarro G. Dopamine in Health and Disease: Much More Than a Neurotransmitter. Biomedicines. 2021;9(2)doi: 10.3390/biomedicines9020109.
Franco, R., Reyes-Resina, I., & Navarro, G. (2021). Dopamine in Health and Disease: Much More Than a Neurotransmitter. Biomedicines, 9(2), . https://doi.org/10.3390/biomedicines9020109
Franco, Rafael, et al. "Dopamine in Health and Disease: Much More Than a Neurotransmitter." Biomedicines vol. 9,2 (2021). doi: https://doi.org/10.3390/biomedicines9020109
Franco R, Reyes-Resina I, Navarro G. Dopamine in Health and Disease: Much More Than a Neurotransmitter. Biomedicines. 2021 Jan 22;9(2). doi: 10.3390/biomedicines9020109. PMID: 33499192; PMCID: PMC7911410.
Copy Download .nbib Format: NLM
Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF).

Evidence-based complementary and alternative medicine : eCAM

Ma S, Zheng L, Lin X, Feng Y, Yang M, Shen L.
PMID: 33995549
Evid Based Complement Alternat Med. 2021 Apr 20;2021:6665137. doi: 10.1155/2021/6665137. eCollection 2021.

BACKGROUND: Da Chuan Xiong Fang (DCXF) is a traditional Chinese medicine (TCM) formula used to treat migraines. Previously, we uncovered partial mechanisms involved in the therapeutic actions of DCXF on migraines.METHODS: In this study, we further elucidated its antimigraine...

Cite
Ma S, Zheng L, Lin X, et al. Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF). Evid Based Complement Alternat Med. 2021;2021:6665137doi: 10.1155/2021/6665137.
Ma, S., Zheng, L., Lin, X., Feng, Y., Yang, M., & Shen, L. (2021). Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF). Evidence-based complementary and alternative medicine : eCAM, 20216665137. https://doi.org/10.1155/2021/6665137
Ma, Shiyu, et al. "Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF)." Evidence-based complementary and alternative medicine : eCAM vol. 2021 (2021): 6665137. doi: https://doi.org/10.1155/2021/6665137
Ma S, Zheng L, Lin X, Feng Y, Yang M, Shen L. Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF). Evid Based Complement Alternat Med. 2021 Apr 20;2021:6665137. doi: 10.1155/2021/6665137. eCollection 2021. PMID: 33995549; PMCID: PMC8081595.
Copy Download .nbib Format: NLM
Manic episode, thyroid gland function and lithium.

Acta neuropsychiatrica

Foeken K, van de Wetering BJ.
PMID: 26956631
Acta Neuropsychiatr. 1992 Sep;4(3):52-6. doi: 10.1017/S0924270800034797.

This paper addresses the issue of (recurrent) mania in relation to an increased T4-value, whether or not influenced by lithium. Lithium has an anti-TSH-effect on the thyroid gland by inhibiting the intracellular enzyme adenylate cyclase. This might cause hypothyroidism....

Cite
Foeken K, van de Wetering BJ. Manic episode, thyroid gland function and lithium. Acta Neuropsychiatr. 1992;4(3):52-6doi: 10.1017/S0924270800034797.
Foeken, K., & van de Wetering, B. J. (1992). Manic episode, thyroid gland function and lithium. Acta neuropsychiatrica, 4(3), 52-6. https://doi.org/10.1017/S0924270800034797
Foeken, K, and van de Wetering, B J. "Manic episode, thyroid gland function and lithium." Acta neuropsychiatrica vol. 4,3 (1992): 52-6. doi: https://doi.org/10.1017/S0924270800034797
Foeken K, van de Wetering BJ. Manic episode, thyroid gland function and lithium. Acta Neuropsychiatr. 1992 Sep;4(3):52-6. doi: 10.1017/S0924270800034797. PMID: 26956631.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries